Docs

Research topics

Peptide drugs

Designing binding peptides from a target protein structure and ranking the candidates computationally — Peptide Drugs.

Why peptides

Peptides sit between small molecules and antibodies. They can take hold of the broad, flat protein–protein interfaces that small molecules struggle to reach, while remaining small enough that design, synthesis, and modification stay fast. As structure prediction and generative models have become practical, designing a binder outright from the target structure has begun to outrun screening.

How the design works

The starting point is the structure of the target protein. Candidate binding peptides are generated from that structure, and binding strength, stability, and physicochemical properties are predicted computationally to prioritise the sequences. Generation opens the field wide and evaluation narrows it, so what matters is not how impressive the generation is but how honest the evaluation is — what decides which candidate goes to the bench is not the absolute score but how much the ranking can be trusted.

Molecular dynamics simulation is one axis of that evaluation, checking on a time axis the binding stability that a static structure prediction misses.

What contextBio does

PepDesigner is this flow turned into a platform — target structure in, peptide generation, molecular-dynamics-based evaluation, and candidate prioritisation, all moved onto a screen. The actual procedure and its limits (the allowed generation length, among others) are written out in its own page.

Carrying a designed candidate through to how it would behave at the level of the cell and the patient is where this meets the virtual cell and virtual hospital work.

Where it stands now

The design pipeline now runs as batch jobs on the GPU cluster, from the target structure through binding-hotspot discovery → generative binder design → structure prediction and filtering → molecular-dynamics simulation → binding free-energy estimation with per-residue decomposition, and — when needed — back around a closed loop of sequence redesign. Boltz-2 is the default structure predictor, and target profiling draws on public databases such as UniProt, PDB, the AlphaFold DB, STRING, ELM and InterPro. This is the actual flow running behind the PepDesigner screens.

Sub-topics

Two strands of this work are written up separately.

  • Generative binder design — the methodology of producing binders with diffusion models and sequence design networks, and the move from one target to several.
  • Immunomodulatory peptides — how the design logic and the evaluation criteria change once the molecule has to face an immune network.

References

61 items

This page draws on the review manuscript Peptide Drug Design Technologies: Current Status, Core Methods, Emerging Innovations, and Future Outlook; below is the literature it cites.

  1. Yen JH, Chang CC, Wu TY, Yang CH, Hsu HJ, Liou JW. Therapeutic peptides and their delivery using lipid-based nanoparticles. Tzu Chi Med J. 2025;37(3):223-234. doi:10.4103/tcmj.tcmj_321_24
  2. Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-based medications for type 2 diabetes and obesity. Endocr Rev. 2026;47(2):159-177. doi:10.1210/endrev/bnaf036
  3. Colas K, Bindl D, Suga H. Selection of nucleotide-encoded mass libraries of macrocyclic peptides for inaccessible drug targets. Chem Rev. 2024;124(21):12213-12241. doi:10.1021/acs.chemrev.4c00422
  4. Cheng J, Zhou J, Kong L, Wang H, Zhang Y, Wang X, et al. Stabilized cyclic peptides as modulators of protein-protein interactions: promising strategies and biological evaluation. RSC Med Chem. 2023;14(12):2496-2508. doi:10.1039/d3md00487b
  5. Previti S, Calcaterra E, González FV, Di Chio C, Calabrò ML, Ettari R, et al. Macrocycles and stapled-peptides in the fight against SARS-CoV-2: a review. Eur J Med Chem. 2026;312:118828. doi:10.1016/j.ejmech.2026.118828
  6. Silvestri AP, Zhang Q, Ping Y, Muir EW, Zhao J, Chakka SK, et al. DNA-encoded macrocyclic peptide libraries enable the discovery of a neutral MDM2-p53 inhibitor. ACS Med Chem Lett. 2023;14(6):820-826. doi:10.1021/acsmedchemlett.3c00117
  7. Yan K, Miskolzie M, Banales Mejia F, Peng C, Ekanayake AI, Atrazhev A, et al. Late-stage reshaping of phage-displayed libraries to macrocyclic and bicyclic landscapes using a multipurpose linchpin. J Am Chem Soc. 2025;147(1):789-800. doi:10.1021/jacs.4c13561
  8. Niu Y, Qin P, Lin P. Advances of deep neural networks (DNNs) in the development of peptide drugs. Future Med Chem. 2025;17(4):485-499. doi:10.1080/17568919.2025.2463319
  9. Padhi AK, Kalita P, Maurya S, Poluri KM, Tripathi T. From design to redesign: harnessing computational protein design for understanding SARS-CoV-2 molecular mechanisms and developing therapeutics. J Phys Chem B. 2023;127(41):8717-8735. doi:10.1021/acs.jpcb.3c04542
  10. Durojaye OA, Uzoeto HO, Okoro NO, Cosmas S, Fadahunsi AA, Bellah SF, et al. Computational biology meets oncology: designing custom protein and peptide binders to outsmart cancer. Med Oncol. 2025;42(8):361. doi:10.1007/s12032-025-02936-6
  11. Sadhukhan S, Bhattacharya R, Bhattcharya D, Sahana S, Pradhan B, Pandit S, et al. Artificial intelligence in protein-based detection and inhibition of AMR pathways. J Comput Aided Mol Des. 2025;40(1):4. doi:10.1007/s10822-025-00710-4
  12. Islam MK, Stanslas J. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. Pharmacol Ther. 2021;227:107870. doi:10.1016/j.pharmthera.2021.107870
  13. Hemmati S, Rasekhi Kazerooni H. Polypharmacological cell-penetrating peptides from venomous marine animals based on immunomodulating, antimicrobial, and anticancer properties. Mar Drugs. 2022;20(12):763. doi:10.3390/md20120763
  14. Falcone N, Ermis M, Tamay DG, Mecwan M, Monirizad M, Mathes TG, et al. Peptide hydrogels as immunomaterials and their use in cancer immunotherapy delivery. Adv Healthc Mater. 2023;12(27):e2301096. doi:10.1002/adhm.202301096
  15. Wichert M, Guasch L, Franzini RM. Challenges and prospects of DNA-encoded library data interpretation. Chem Rev. 2024;124(22):12551-12572. doi:10.1021/acs.chemrev.4c00284
  16. Han S, Guo X, Wang M, Liu H, Song Y, He Y, et al. Highly selective novel heme oxygenase-1 hits found by DNA-encoded library machine learning beyond the DEL chemical space. ACS Med Chem Lett. 2024;15(9):1456-1466. doi:10.1021/acsmedchemlett.4c00121
  17. Lee K, Willi JA, Cho N, Kim I, Jewett MC, Lee J. Cell-free biosynthesis of peptidomimetics. Biotechnol Bioprocess Eng. 2023;28(1):1-17. doi:10.1007/s12257-022-0268-5
  18. Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: a review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025;52(7):2685-2709. doi:10.1007/s00259-025-07103-7
  19. Wohlwend J, Corso G, Passaro S, Getz N, Reveiz M, Leidal K, et al. Boltz-1: democratizing biomolecular interaction modeling. bioRxiv. 2024. doi:10.1101/2024.11.19.624167
  20. Passaro S, Corso G, Wohlwend J, Reveiz M, Thaler S, Somnath VR, et al. Boltz-2: towards accurate and efficient binding affinity prediction. bioRxiv. 2025. doi:10.1101/2025.06.14.659707
  21. Takaba K, Watanabe C, Tokuhisa A, Akinaga Y, Ma B, Kanada R, et al. Protein-ligand binding affinity prediction of cyclin-dependent kinase-2 inhibitors by dynamically averaged fragment molecular orbital-based interaction energy. J Comput Chem. 2022;43(20):1362-1371. doi:10.1002/jcc.26940
  22. Yuan Z, Zhang M, Chang L, Chen X, Ruan S, Shi S, et al. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation. J Mol Model. 2024;30(5):131. doi:10.1007/s00894-024-05935-y
  23. Jin H, Kim J, Lee O, Kim H, No KT. Leveraging the fragment molecular orbital method to explore the PLK1 kinase binding site and polo-box domain for potent small-molecule drug design. Int J Mol Sci. 2023;24(21):15639. doi:10.3390/ijms242115639
  24. Onishi M, Taguchi T, Masuda A, Fukuzawa K. Fragment molecular orbital calculation analysis of influenza neuraminidase and inhibitor interactions. Yakugaku Zasshi. 2026;146(6). doi:10.1248/yakushi.25-00187
  25. Shah M, Moon SU, Choi JH, Kim MJ, Woo HG. Peptide-based therapeutics targeting the SLC39A14-PIWIL2 fusion in hepatocellular carcinoma. Genomics Inform. 2025;23(1):28. doi:10.1186/s44342-025-00060-5
  26. Ghulam A, Rehman M, Fida H, Zhao PY, Noroze R, Qi YC, et al. AMP-CapsNet: a multi-view feature fusion approach for antimicrobial peptide prediction using capsule networks. Genomics Inform. 2026;24(1). doi:10.1186/s44342-026-00067-6
  27. Noori Goodarzi N, Fereshteh S, Shahbazi B, Rezaie N, Khazani Asforooshani M, Badmasti F. Design of a multi-epitope vaccine against Mycobacterium tuberculosis using reverse vaccinology and immunoreactive peptides. Genomics Inform. 2026;24(1). doi:10.1186/s44342-026-00075-6
  28. Conde-Torres D, Mussa-Juane M, Faílde D, Gómez A, García-Fandiño R, Piñeiro Á. Classical simulations on quantum computers: interface-driven peptide folding on simulated membrane surfaces. Comput Biol Med. 2024;182:109157. doi:10.1016/j.compbiomed.2024.109157
  29. Rettie SA, Juergens D, Adebomi V, Bueso YF, Zhao Q, Leveille AN, et al. Accurate de novo design of high-affinity protein-binding macrocycles using deep learning. Nat Chem Biol. 2025;21(12):1948-1956. doi:10.1038/s41589-025-01929-w
  30. Rettie SA, Campbell KV, Bera AK, Kang A, Kozlov S, Bueso YF, et al. Cyclic peptide structure prediction and design using AlphaFold2. Nat Commun. 2025;16(1):4730. doi:10.1038/s41467-025-59940-7
  31. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74. doi:10.1038/s41392-024-02107-5
  32. Hoeg-Jensen T, Kruse T, Brand CL, Sturis J, Fledelius C, Nielsen PK, et al. Glucose-sensitive insulin with attenuation of hypoglycaemia. Nature. 2024;634(8035):944-951. doi:10.1038/s41586-024-08042-3
  33. Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, et al. Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nat Med. 2025;31(8):2722-2736. doi:10.1038/s41591-025-03704-9
  34. Wang B, Lin P, Zhong Y, Tan X, Shen Y, Huang Y, et al. Explainable deep learning and virtual evolution identifies antimicrobial peptides with activity against multidrug-resistant human pathogens. Nat Microbiol. 2025;10(2):332-347. doi:10.1038/s41564-024-01907-3
  35. Liu H, Song Z, Zhang Y, Wu B, Chen D, Zhou Z, et al. De novo design of self-assembling peptides with antimicrobial activity guided by deep learning. Nat Mater. 2025;24(8):1295-1306. doi:10.1038/s41563-025-02164-3
  36. Wang X, Guillem-Marti J, Kumar S, Lee DS, Cabrerizo-Aguado D, Werther R, et al. De novo design of integrin α5β1 modulating proteins to enhance biomaterial properties. Adv Mater. 2025;37(34):e2500872. doi:10.1002/adma.202500872
  37. Szymczak P, Zarzecki W, Wang J, Duan Y, Wang J, Coelho LP, et al. AI-driven antimicrobial peptide discovery: mining and generation. Acc Chem Res. 2025;58(12):1831-1846. doi:10.1021/acs.accounts.0c00594
  38. Singh S, Gleason CE, Fang M, Laimon YN, Khivansara V, Xie S, et al. Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors. Nature. 2025;646(8085):734-745. doi:10.1038/s41586-025-09433-w
  39. Ochoa D, Hercules A, Carmona M, Suveges D, Baker J, Malangone C, et al. The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Res. 2023;51(D1):D1353-D1359. doi:10.1093/nar/gkac1046
  40. Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics. 2009;10:168. doi:10.1186/1471-2105-10-168
  41. Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, et al. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat Protoc. 2015;10(5):733-755. doi:10.1038/nprot.2015.043
  42. Kortemme T, Baker D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc Natl Acad Sci U S A. 2002;99(22):14116-14121. doi:10.1073/pnas.202485799
  43. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33(Web Server issue):W382-W388. doi:10.1093/nar/gki387
  44. Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W, et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science. 2023;379(6637):1123-1130. doi:10.1126/science.ade2574
  45. Evans R, O'Neill M, Pritzel A, Antropova N, Senior A, Green T, et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv. 2022. doi:10.1101/2021.10.04.463034
  46. Lamiable A, Thévenet P, Rey J, Vavrusa M, Derreumaux P, Tufféry P. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. 2016;44(W1):W449-W454. doi:10.1093/nar/gkw329
  47. Zhou P, Jin B, Li H, Huang SY. HPEPDOCK: a web server for blind peptide-protein docking based on a hierarchical algorithm. Nucleic Acids Res. 2018;46(W1):W443-W450. doi:10.1093/nar/gky357
  48. Zhang Y, Sanner MF. AutoDock CrankPep: combining folding and docking to predict protein-peptide complexes. Bioinformatics. 2019;35(24):5121-5127. doi:10.1093/bioinformatics/btz459
  49. Raveh B, London N, Schueler-Furman O. Sub-angstrom modeling of complexes between flexible peptides and globular proteins. Proteins. 2010;78(9):2029-2040. doi:10.1002/prot.22716
  50. Dauparas J, Anishchenko I, Bennett N, Bai H, Ragotte RJ, Milles LF, et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science. 2022;378(6615):49-56. doi:10.1126/science.add2187
  51. Krishna R, Wang J, Ahern W, Sturmfels P, Venkatesh P, Kalvet I, et al. Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science. 2024;384(6693):eadl2528. doi:10.1126/science.adl2528
  52. Mandell DJ, Coutsias EA, Kortemme T. Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling. Nat Methods. 2009;6(8):551-552. doi:10.1038/nmeth0809-551
  53. Stein A, Kortemme T. Improvements to robotics-inspired conformational sampling in Rosetta. PLoS One. 2013;8(5):e63090. doi:10.1371/journal.pone.0063090
  54. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19-25. doi:10.1016/j.softx.2015.06.001
  55. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668-1688. doi:10.1002/jcc.20290
  56. Eastman P, Swails J, Chodera JD, McGibbon RT, Zhao Y, Beauchamp KA, et al. OpenMM 7: rapid development of high performance algorithms for molecular dynamics. PLoS Comput Biol. 2017;13(7):e1005659. doi:10.1371/journal.pcbi.1005659
  57. Tribello GA, Bonomi M, Branduardi D, Camilloni C, Bussi G. PLUMED 2: new feathers for an old bird. Comput Phys Commun. 2014;185(2):604-613. doi:10.1016/j.cpc.2013.09.018
  58. Valdés-Tresanco MS, Valdés-Tresanco ME, Valiente PA, Moreno E. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput. 2021;17(10):6281-6291. doi:10.1021/acs.jctc.1c00645
  59. Miller BR 3rd, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012;8(9):3314-3321. doi:10.1021/ct300418h
  60. Conchillo-Solé O, de Groot NS, Avilés FX, Vendrell J, Daura X, Ventura S. AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics. 2007;8:65. doi:10.1186/1471-2105-8-65
  61. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004;22(10):1302-1306. doi:10.1038/nbt1012 Figure 1. Convergent, multi-resolution pipeline for computational peptide drug design. A therapeutic target, often a large protein-protein interface historically deemed undruggable, enters a closed design-build-test loop assembled from four algorithmic families: deep-learning structure prediction (AlphaFold2 and AlphaFold3-class models and open reimplementations such as Boltz-1 and Boltz-2); generative de novo design (denoising-diffusion backbone generation with RFdiffusion and RFpeptides, AlphaFold2 hallucination with AfCycDesign, and sequence-space generative models); physics-based and quantum-mechanical scoring (molecular-dynamics MM/PBSA and MM/GBSA free-energy estimation and fragment molecular orbital analysis); and machine learning on DNA-encoded libraries. Computationally proposed peptides are stabilized by stapling, macrocyclization, and non-canonical amino acids and equipped for delivery as radioconjugates, lipid-nanoparticle formulations, or hydrogel depots, yielding candidate therapeutics deployed across metabolic disease, oncology, and infection. High-throughput experiment returns data that retrains the models, closing the active-learning loop.

Last updated ·